https://www.selleckchem.com/pr....oducts/pentetic-acid
95% cumulative lung-cancer risk, would also refer 76% of participants to a 2-year interval, but would delay diagnosis for only 30% of cancers, a 25% reduction versus the NHS protocol. Alternatively, LCRAT+CT, with a threshold of 1.7% cumulative lung-cancer risk, would also delay diagnosis for 40% of cancers, but would refer 85% of participants for a 2-year interval, a 38% further reduction in the number of required 1-year screens beyond the NHS protocol. Using individualized risk models to determine management in lung cancer s
Like
Comment
Share
